The future of market access: from pricing to value creation

From reactive function to strategic partner

Market access is becoming involved increasingly early in the development of new medicines. Decisions made during the preclinical and clinical development phases directly affect eventual reimbursement, market acceptance and commercial performance. Organisations that integrate market access only after pivotal registration studies risk lacking the essential evidence required to substantiate the added value of a therapy convincingly.

Leading organisations are therefore increasingly establishing integrated teams in which clinical development, medical affairs, health economics and outcomes research (HEOR), regulatory affairs and commercial functions collaborate closely from the early stages of development. This multidisciplinary approach ensures that clinical endpoints, economic analyses and evidence generation strategies align with the expectations of healthcare authorities and payers.

Demonstrating value requires more than clinical efficacy

Although safety and efficacy remain the basis for marketing authorisation, these factors alone are no longer sufficient to secure broad reimbursement. Healthcare systems increasingly expect evidence of a treatment’s wider societal and economic impact.

In addition to clinical data, organisations must therefore invest in:

• Health economics and outcomes research (HEOR);

• Real-world evidence (RWE);

• Patient-reported outcomes (PROs);

• Budget impact analyses;

• Long-term outcomes and health gains;

• Comparative effectiveness studies.

  
  

This additional body of evidence increasingly provides the foundation for successful pricing and reimbursement negotiations.

The growing role of real-world evidence

Real-world evidence is rapidly becoming an essential component of modern market access strategies. While traditional clinical trials demonstrate efficacy under controlled conditions, RWE shows how a therapy performs in routine clinical practice.

For health insurers, health technology assessment (HTA) bodies and governments, this information provides valuable insights into treatment outcomes, adherence, quality of life and cost-effectiveness. Organisations capable of integrating real-world data effectively are in a significantly stronger position when negotiating reimbursement and seeking future indication expansions.

Early stakeholder engagement as a competitive advantage

The most successful organisations do not wait until registration to engage with external stakeholders. Early interaction with HTA bodies, healthcare authorities, clinicians, patient organisations and payers helps identify expectations at an early stage and align development programmes accordingly.

This proactive approach reduces uncertainty, shortens the time to reimbursement and increases the likelihood of successful market launches. It also creates a better understanding of which clinical and economic outcomes are genuinely relevant to decision-makers across different healthcare systems.

From national strategy to global complexity

For internationally operating life sciences organisations, the complexity is even greater. Although the scientific basis of a therapy remains the same worldwide, pricing, reimbursement and HTA requirements differ considerably between countries.

Successful market access strategies therefore combine a consistent global value proposition with sufficient flexibility to address national regulations, local healthcare priorities and differing reimbursement models. The ability to achieve this balance is becoming an increasingly important differentiator in international product launches.